Central Nervous System News and Research

RSS

Study suggests potential treatment for cardiovascular disease in people with apoE4 gene variant

Researchers at UT-Southwestern Medical Center have found that the most common variant of the circulating protein apolipoprotein E, called apoE3, helps repair the lining of blood vessels. Individuals with another variant, called apoE4, do not get the benefit of this repair, putting them at higher risk for cardiovascular disease.

18 Sep 2014

Researchers gain new knowledge about complex processes that cause Parkinson's disease

Using advanced computer models, neuroscience researchers at the University of Copenhagen have gained new knowledge about the complex processes that cause Parkinson's disease. The findings have recently been published in the prestigious Journal of Neuroscience.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Pollution in many cities threatens brain development in children

Pollution in many cities threatens the brain development in children. Findings by University of Montana Professor Dr. Lilian Calder-n-Garcidue-as, MA, MD, Ph.D., and her team of researchers reveal that children living in megacities are at increased risk for brain inflammation and neurodegenerative changes, including Alzheimer's or Parkinson's disease.

11 Sep 2014

Fogarty receives three grants for research focused on biodiversity conservation

In addition to diseases for which there are ineffective or no cures, key pathogens are becoming increasingly drug-resistant.

10 Sep 2014

People with multiple sclerosis lose myelin in gray matter

People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic resonance imaging (MRI) study.

10 Sep 2014

People with increased yellow in macula could maintain better vision: Study

Human eyes naturally contain yellow pigment in the macula, a spot near the center of the retina responsible for high-resolution vision. Those with more yellow in their macula may have an advantage when it comes to filtering out atmospheric particles that obscure one's vision, commonly known as haze.

5 Sep 2014

Findings may help develop biomarkers to identify HIV patients at risk of dementia

Since the introduction of the combination anti-retroviral therapy (cART) in the mid-90s, the life expectancy of HIV patients has significantly improved. As a result, long-term complications are becoming more relevant: almost every second HIV patient is affected by neurocognitive disorders, which can lead to dementia.

4 Sep 2014

Study investigates whether function of intestines attacked in MS

The present study investigates whether the function of the intestines is also attacked in MS. The results, obtained from a disease model of MS in mice, shows inflammation and changes in the barrier function of the intestines early in the course of the disease.

4 Sep 2014

Yoga program for MS patients improves physical and mental well-being

Paula Meltzer was only 38 when out of nowhere everything she looked at was blurry. For the single mother, who had a lucrative career as a gemologist and spent hours examining valuable pieces of jewelry, it seemed as if - in a split second - her life changed.

3 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

27 Aug 2014

Study examines ocular changes seen in astronauts to treat spaceflight-induced visual impairment

To reduce and better treat spaceflight-induced visual impairment, University of Houston (UH) optometrists are collaborating on a NASA study that examines ocular changes seen in a number of astronauts.

27 Aug 2014

Use of VISIUS iMRI in brain tumor surgery results in complete tumor removal

IMRIS Inc. today announced that a recently published article in the journal Neurosurgery is the highest level clinical evidence to show that the use of VISIUS® intraoperative MRI in brain tumor surgery results in complete tumor removal in more patients with glioma tumors.

26 Aug 2014

Balance board accessory can help people with MS reduce risk of accidental falls

A balance board accessory for a popular video game console can help people with multiple sclerosis (MS) reduce their risk of accidental falls, according to new research published online in the journal Radiology.

26 Aug 2014

Researchers find roving detection system for treating cancer, Parkinson's disease and ALS

Duke University researchers have found a "roving detection system" on the surface of cells that may point to new ways of treating diseases like cancer, Parkinson's disease and amyotrophic lateral sclerosis (ALS).

26 Aug 2014

NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group.

21 Aug 2014

Research validates Myc inhibition as effective therapeutic strategy for glioma

Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.

19 Aug 2014

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors.

15 Aug 2014

Central Nervous System News and Research

Study suggests potential treatment for cardiovascular disease in people with apoE4 gene variant

Researchers gain new knowledge about complex processes that cause Parkinson's disease

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Pollution in many cities threatens brain development in children

Fogarty receives three grants for research focused on biodiversity conservation

People with multiple sclerosis lose myelin in gray matter

People with increased yellow in macula could maintain better vision: Study

Findings may help develop biomarkers to identify HIV patients at risk of dementia

Study investigates whether function of intestines attacked in MS

Yoga program for MS patients improves physical and mental well-being

Synthetic announces positive results from final preclinical toxicology study of SYN-004

New MS treatment found safe, tolerable in phase I clinical trials

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Study examines ocular changes seen in astronauts to treat spaceflight-induced visual impairment

Use of VISIUS iMRI in brain tumor surgery results in complete tumor removal

Balance board accessory can help people with MS reduce risk of accidental falls

Researchers find roving detection system for treating cancer, Parkinson's disease and ALS

NeuroDerm signs definitive investment agreements for $16 million financing round

Research validates Myc inhibition as effective therapeutic strategy for glioma

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Event guide: The 7th CNS Drug Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News